Several other research firms have also recently commented on SLGL. Zacks Investment Research raised Sol Gel Technologies from a sell rating to a hold rating in a research note on Friday, June 22nd. ValuEngine raised Sol Gel Technologies from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $19.00.
Sol Gel Technologies traded up $0.13, hitting $6.54, on Thursday, according to Marketbeat.com. 2,278 shares of the company were exchanged, compared to its average volume of 15,263. Sol Gel Technologies has a twelve month low of $6.18 and a twelve month high of $16.48.
Sol Gel Technologies (NASDAQ:SLGL) last released its earnings results on Wednesday, August 8th. The company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.12. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. research analysts forecast that Sol Gel Technologies will post -2.05 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new stake in Sol Gel Technologies during the 1st quarter worth about $103,000. DAFNA Capital Management LLC purchased a new stake in Sol Gel Technologies during the 1st quarter worth about $361,000. Guggenheim Capital LLC purchased a new stake in Sol Gel Technologies during the 1st quarter worth about $1,073,000. Nexthera Capital LP purchased a new stake in Sol Gel Technologies during the 1st quarter worth about $5,334,000. Finally, Delek Group Ltd. lifted its holdings in Sol Gel Technologies by 22.3% during the 2nd quarter. Delek Group Ltd. now owns 1,269,816 shares of the company’s stock worth $9,803,000 after buying an additional 231,786 shares during the last quarter. 22.32% of the stock is owned by institutional investors.
About Sol Gel Technologies
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Read More: How to Use the New Google Finance Tool
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.